Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gastroenterol Hepatol. 2023;8(4):332–342

Article  CAS  PubMed  Google Scholar 

World Health Organization. Global Hepatitis Report 2017 2017. Available from: https://www.who.int/publications/i/item/global-hepatitis-report-2017.

Hui RW, Mak LY, Cheung TT, Lee VH, Seto WK, Yuen MF. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2022;29(2):217–229

Article  PubMed  PubMed Central  Google Scholar 

Nguyen VH, Huang DQ, Le MH, Jin M, Lee EY, Henry L, et al. Global treatment rate and barriers to direct-acting antiviral therapy: a systematic review and meta-analysis of 146 studies and 1 760 352 hepatitis C virus patients. Liver Int. 2023;43(6):1195–1203

Article  CAS  PubMed  Google Scholar 

Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–2324

Article  PubMed  Google Scholar 

Ghany MG, Buti M, Lampertico P, Lee HM. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV treatment endpoints conference. Hepatology. 2023;78(5):1654–1673

Article  PubMed  Google Scholar 

Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44(10):1071–1079

Article  CAS  PubMed  Google Scholar 

Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepatitis. 2019;26(7):818–827

Article  CAS  Google Scholar 

Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475

Article  CAS  PubMed  Google Scholar 

Cheung KS, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, et al. Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis. Clin Transl Gastroenterol. 2020;11(10): e00236

Article  PubMed  PubMed Central  Google Scholar 

Wu CY, Lin JT, Ho HJ, Su CW, Lee TY, Wang SY, et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology. 2014;147(1):143–51.e5

Article  CAS  PubMed  Google Scholar 

Kudaravalli S, Huang DQ, Yeh ML, Trinh L, Tsai PC, Hsu YC, et al. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world. J Hepatol. 2024;81(1):33–41

Article  PubMed  Google Scholar 

World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection 2024. Available from: https://www.who.int/publications/i/item/9789240090903.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599

Article  PubMed  Google Scholar 

European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–398

Article  Google Scholar 

Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98

Article  CAS  PubMed  Google Scholar 

Razavi H, Musabaev E, Sadirova S, Razavi-Shearer K, Bakieva S, Brigida K. The impact of removing all hepatitis B virus (HBV) testing and treatment restrictions. J Hepatol. 2023;78:S888–S889

Article  Google Scholar 

Su F, Jacobson IM. Chronic hepatitis B: treat all who are viremic? Clin Liver Dis. 2023;27(4):791–808

Article  PubMed  Google Scholar 

Lim YS, Kim WR, Dieterich D, Kao JH, Flaherty JF, Yee LJ, et al. Evidence for benefits of early treatment initiation for chronic hepatitis B. Viruses. 2023;15(4):997

Article  CAS  PubMed  PubMed Central  Google Scholar 

You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11(6):1425–1442

PubMed  PubMed Central  Google Scholar 

Martin P, Nguyen MH, Dieterich DT, Lau DT, Janssen HLA, Peters MG, et al. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 update. Clin Gastroenterol Hepatol. 2022;20(8):1766–1775

Article  PubMed  Google Scholar 

Dieterich D, Graham C, Wang S, Kwo P, Lim YS, Liu CJ, et al. It is time for a simplified approach to hepatitis B elimination. Gastro Hep Adv. 2023;2(2):209–218

Article  PubMed  Google Scholar 

Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther. 2020;52(10):1540–1550

Article  CAS  PubMed  Google Scholar 

Hepatitis B Primary Care Workgroup. Hepatitis B management: guidance for the primary care provider 2020. Available from: https://www.hepatitisb.uw.edu/page/primary-care-workgroup/guidance.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73

Article  CAS  PubMed  Google Scholar 

Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–686

Article  PubMed  Google Scholar 

Iloeje UH, Yang HI, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol. 2007;5(8):921–931

Article  PubMed  Google Scholar 

Yuen MF. Biological gradient of chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2021;18(9):593

Article  PubMed  Google Scholar 

Ching RHH, Sze KMF, Lau EYT, Chiu YT, Lee JMF, Ng IOL, et al. C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. Oncotarget. 2017;8(14):23507–23516

Article  PubMed  PubMed Central  Google Scholar 

Sze KM, Chu GK, Lee JM, Ng IO. C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. Hepatology. 2013;57(1):131–139

Article  CAS  PubMed  Google Scholar 

Hui RW, Wong DK, Ho DW, Lyu X, Mak LY, Fung J, et al. HBV DNA integration profiles in the natural history of chronic hepatitis B. Hep Intl. 2024;18(Suppl1):50–51

Google Scholar 

Lim YS. Gray zone of hepatitis B virus infection. Saudi J Gastroenterol. 2023;30(2):76–82

Article  PubMed  PubMed Central  Google Scholar 

Mak LY, Yee LJ, Wong RJ, Ramers CB, Frenette C, Hsu YC. Hepatocellular carcinoma among patients with chronic hepatitis B in the indeterminate phase. J Viral Hepatitis. 2024;31(S2):27–35

Article  Google Scholar 

Wang J, Yan X, Zhu L, Liu J, Qiu Y, Li Y, et al. Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone. Aliment Pharmacol Ther. 2023;57(5):464–474

Article  CAS  PubMed  Google Scholar 

Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134(5):1376–1384

Article  PubMed  Google Scholar 

Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol. 2008;6(5):569–574